Cargando…
A metabolic biosignature of early response to anti-tuberculosis treatment
BACKGROUND: The successful treatment of tuberculosis (TB) requires long-term multidrug chemotherapy. Clinical trials to evaluate new drugs and regimens for TB treatment are protracted due to the slow clearance of Mycobacterium tuberculosis (Mtb) infection and the lack of early biomarkers to predict...
Autores principales: | Mahapatra, Sebabrata, Hess, Ann M, Johnson, John L, Eisenach, Kathleen D, DeGroote, Mary A, Gitta, Phineas, Joloba, Moses L, Kaplan, Gilla, Walzl, Gerhard, Boom, W Henry, Belisle, John T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918231/ https://www.ncbi.nlm.nih.gov/pubmed/24484441 http://dx.doi.org/10.1186/1471-2334-14-53 |
Ejemplares similares
-
Elucidation of a Human Urine Metabolite as a Seryl-Leucine
Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy
por: Fitzgerald, Bryna L., et al.
Publicado: (2018) -
Correction to “Elucidation of a Novel Human
Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker
of Effective Anti-Tuberculosis Therapy”
por: Fitzgerald, Bryna L., et al.
Publicado: (2019) -
Biosignatures: The answer to Tuberculosis diagnosis in children?
por: Goussard, Pierre, et al.
Publicado: (2020) -
Distinct serum biosignatures are associated with different tuberculosis treatment outcomes
por: Ronacher, Katharina, et al.
Publicado: (2019) -
Long-term dominance of Mycobacterium tuberculosis Uganda family in peri-urban Kampala-Uganda is not associated with cavitary disease
por: Wampande, Eddie M, et al.
Publicado: (2013)